Blog

Hello HOPEians,

Please find below the action items from the RF3 meeting on June 5, 2023. If you have any questions about the meeting or action items please reach out to Dr. Melanie Ott and Dr. Priti Kumar. 

 

Updates:

Rubens Almeida-Tavora: Homing Endonucleases

Rubens shared his work on the use of homing endonucleases to inactive adeno-associated virus transgene expression. They are using the Adeno-associated virus (rAAV) as an in vivo gene therapy platform. rAAV has broad tropism, low immunogenicity, and lack of pathogenesis but can also achieve the long-term expression of transgenes. AAV gene therapy can be used to treat hemophilia A.

Rubens shared a study on the functionally cured “Miami Monkey”.  Rhesus macaques infected with SHIV and AAV delivery of monoclonal antibodies showed little to no SHIV viral load. There are pros and cons to the long-term expression of AAV. It is currently impossible to halt AAV expression in case of adverse events. To inactivate AAV transgene expression, we have turned to Homing Endonucleases.

Homing Endonucleases (HEs) are naturally expressed “selfish” mobile genetic elements found across a wide range of organisms. They promote their own propagation through targeted recombination and have many characteristics that are perfect for our goal. In order to screen naturally occurring HE’s, Rubens and colleagues utilized a luciferase-based platform. They compared the toxicity of their three best HEs and designed inactive endonucleases to serve as negative controls. To help improve their target construct, they will change the location and add more targets.

Rubens shared the paper published in Nature on  “Interruption of coding sequences by heterologous introns can enhance the functional expression of recombinant genes”. The study showed that placing introns within the coding region of a gene can significantly increase transgene expression. Using this technology, Rubens and colleagues were able to make improvements to the target construction by implementing new intron technology for Anil-Y2, Bmol, and Ppol reporters. 

Additionally, they introduced an Anil-Y2 within the OSM signal sequence to further improve the target reporter. This can significantly contribute to transgene inactivation. Rubens explained further the design of mRNA expressing HE, LNP delivered HEs toxicity profile, alternative approaches, and the design of their in vivo experiments.

Other Updates:

We also heard quick updates from Ulrike, Fran, and Yaping. Ulrike shared data from their focus meetings on production for specific AAVs in mice. They are looking for biodistribution and want to boost expression for Brec1. Fran shared the Lenti usable dock system for brec1. The doc-inducible dBrec1 and Brecoff express and bind to HIV LTR. They will introduce Doxo and find out why it is not working in JLats. Yaping is working with primary t-cells and improving efficiency on the CCR5 and TAR base editing. The single base mutation was confirmed from sequencing data and it will be hard to transfect cells CCR14.

In the next RF3 meeting, we will hear more updates from Fran on jLat results and from Yaping on CCR5 and TAR base editing data.

Announcements

• Check out the Community Jam Board to help address some of our community’s concerns

• The HOPE Collaboratory-wide meeting is July 24th 9am PT/12pm ET.. 

• The next RF3 meetings is August 7th

• Upcoming Speakers:

  • June 15     Dr. Mimi Ghosh

  • June 26     Drs. Steven Deeks & Michael Peluso

• Please Acknowledge HOPE & the NIH in any publications or presentations and notify the Program Manager. Here are some examples of what you can include. 

“Research reported in this publication was supported by the NIAID of the National Institutes of Health under award number UM1AI164559, with co-funding support from NIDA, NIMH, NHLBI, the NIDDK, and the NINDS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

“This research was supported by NIAID award number UM1AI164559, co-funded by NHLBI, NIDA, NIMH, NINDS, and NIDDK.”

Hello HOPEians,

Please find below the action items from the RF3 meeting on April 3, 2023. If you have any questions about the meeting or action items please reach out to Dr. Melanie Ott and Dr. Priti Kumar.

Updates:

Today we heard updates about Niren’s acid-degradable LNPs data. His project goals are to develop LNP/mRNA complexes that can deliver gene editor mRNA to T cells and HPSCs. LNPs made with acid-degradable lipids should disrupt endosomes efficiently and have lower tissue accumulation. Acid-degradable LNPs transfect a variety of non-liver organs in mice, including the liver, spleen, and heart. LNPs with acid-degradable PEG chains transfect the bone marrow and spleen and HSPCs in vitro with low toxicity. However, myeloid populations appear to be the main transfected population, rather than T cells.  Low doses of LNPs with acid-degradable negative lipids transfect 5% of the CD3+ cells in the spleen. The Murthy Lab confirmed ZsGreen positive cells in BM reproducibly and detected ZsGreen positive cells in peripheral blood cells. They can target ST-HSC in vivo and can detect the ZsGreen signal in almost all hematopoietic lineages.

New lipids can be synthesized rapidly via solid-phase synthesis. Peptide-lipids generated via solid-phase synthesis can transfect primary T-cells. Heavily modified gRNAs increase the gene editing efficiency of LNP-delivered CAS9 mRNA in primary neurons (derived from iPSC). Niren shared the paper: A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

We also heard updates from Martin Hamann on AAV-mediated Brec1 delivery and an overview of their cell models. Brec1 delivered by lentivirus leads to the excision of HIV-BFP reporter. Initially, there is little to no Brec1-mediated recombination seen in any of their reporter lines when delivered with AAV. They tested optimized Brec-1 ORF, exchanged promoters, and utilized multiple AAV serotypes and MOI. The reasons were not clear but there was no recombination in SupT1 cell lines. There was suboptimal transgene expression in primary cells. In the future, they will test AAV-Brec1 on HeLa-Smurf and Jurkat-Smurf to complement their data.  They will compare transcription levels of Brec1 mRNA in HeLa and SupT1 cells, optimize AAV transduction in SupT1/Primary T cells, and treat with compounds known to boost transgene expression in T cells. Martin shared the paper: Extracellular nanovesicles for packaging of CRISPR cas9 proteins and sgRNA to induce therapeutic exon skipping.

In the next RF3 meeting, we will brainstorm potential RF3 speakers for the HOPE Annual Meeting and go through previous actions.

Actions:

• Kumar Lab – Send the Ott lab the mutated sequences (Sequencing clones in Jurkats, VLPs to express base editors that can mutate and fight the response) Ursula Schulze-Gahmen can test for TAR structures
• Kumar lab – Test if you can use dead Cas9 for base editing
• Ott and Kumar lab – Send Ulrike the constructs to test. Schedule a call to test this
• Ulrike/Fran- send Kumar lab the constructs (dead Brec1 with fusion)
• Niren – Combine and put a PEG coding on the PLGA, use conjugation coding, and do this at the beginning. Try more extensive pegylation
• Kumar lab- Connect with Ursula for biochemistry for host gene targeting
• Bring Esper onto RF3 to address their global solutions concerns
• Michael – Share mice tissue flash freezing protocols with Priti
  • Priti can test materials sent
• Niren – Send LNPs to Priti for the Kumar lab to test – Transfection of primary human t cells with aptamer target LNPs with heart tissues
• Ulrike meeting with Fran to look at data from a previous student for Brec off suppression
  • Ulrike-Docs inducible vectors, prepping DNA, send maps and constructs to Fran
  • Send new AV to Priti
• Lish – work on MTA for this (Brec, latency models), Ulrike to send MTA contact officer to Lish

 

Announcements

• Check out the Community Jam Board to help address some of our community’s concerns
• The HOPE Collaboratory-wide meeting is May 22nd 9am PT/12pm ET
• The next RF3 meeting is June 5th
• Upcoming Speakers:
  • April 24     Dr. Jon Karn
  • May 1       Dr. Jeannette Tenthorey
  • May 15     Dr. Steve Yukl
• Please Acknowledge HOPE & the NIH in any publications or presentations and notify the Program Manager. Here are some examples of what you can include.

“Research reported in this publication was supported by the NIAID of the National Institutes of Health under award number UM1AI164559, with co-funding support from NIDA, NIMH, NHLBI, the NIDDK, and the NINDS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

“This research was supported by NIAID award number UM1AI164559, co-funded by NHLBI, NIDA, NIMH, NINDS, and NIDDK.”

Hello HOPEians,

Please find below the action items from the RF3 meeting on February 6, 2023. If you have any questions about the meeting or action items please reach out to Dr. Melanie Ott and Dr. Priti Kumar.

Updates:

Today we discussed the benefits of targeting CCR5 for mutagenesis and heard updates from the Kumar lab. The SAB suggested using a dual approach to help prevent future infections by targeting both the proviral genome and a host restriction factor. The caveat is that if only 30-40% of T cells have the CCR5 mutation, the viral rebound will undoubtedly occur prior to mutated cells taking over the cell milieu. Targeting efficiency has to be very high (perhaps >95%) and ideally be done in vivo; however, this is hard to achieve with nanoparticles. Up to a point, viral rebound is okay because you don’t change the size of the reservoir. There is an argument for going after the virus using something like laser ART in the most important tissue reservoirs where virus rebound can perhaps be staved off allowing time for repeated treatment with the gene editing approach. Laser ART is a nanoparticle-based ART approach that allows the slow release of ART at high concentrations in tissue reservoirs.

The Kumar lab is currently working on understanding the mutations induced by VLP-delivered CRISPR-base editors of HIV-1 provirus in Jurkat cells by sequencing the target. They are testing different guide RNAs and in the next couple of months hope to switch to mouse experiments. The lab is also adapting a base-editing approach for targeting CCR5 and CXCR4 for combination therapy.

Ott lab shared that Francisco transfects 30-40% TZMBL cells and then sorts cells with plasma DNA and not in Jurkats (TZM-bL cells are HELA cells with an integrated HIV-LTR luciferase reporter gene).

In the next RF3 meeting, we will hear from Fran and Ulrike about Brec1 delivery and what models they have used, and base editing

Here are some papers shared in today’s meeting:

• Functional T cells are capable of supernumerary cell division and longevity
• Methods and compositions for RNA-guided treatment of HIV infection

 

Actions:

• Kumar Lab – Send the Ott lab the mutated sequences obtained after base editing so Ursula Schulze-Gahmen can test for TAR structures
• Kumar lab – Test if you can use dead Brec 1 for base editing
• Ott and Kumar lab – Send Ulrike the constructs to test. Schedule a call to test this
• Ulrike/Fran- send Kumar lab the constructs (dead Brec1 with fusion)
• Niren – Combine and put a PEG coding on the PLGA, use conjugation coding, and do this at the beginning. Try more extensive pegylation
• Kumar lab- Connect with Ursula for biochemistry for host gene targeting
• Bring Esper onto RF3 to address their global solutions concerns
• Fran – send paper
• Michael – Share mice tissue flash freezing protocols with Priti

• • Priti can test materials sent

• Niren – Send LNPs to Priti for the Kumar lab to test – Transfection of primary human t cells with aptamer target LNPs with heart tissues
• Ulrike meeting with Fran to look at data from a previous student for Brec off suppression

• • Ulrike-Docs inducible vectors, prepping DNA, send maps and constructs to Fran
  • Send new AV to Priti

• Lish – work on MTA for this (Brec, latency models), Ulrike to send MTA contact officer to Lish

 

Announcements:

• CRISPR for Cure – Webinar Friday, February 10th, 12-1pm PT / 3pm ET

• • Join Zoom Meeting https://temple.zoom.us/j/94549370930

• Check out the Community Jam Board to help address some of our community’s concerns
• The HOPE Collaboratory-wide meeting is on March 27.
• The next RF3 Meeting is on April 3rd. Please come prepared with some updates.
• Please Acknowledge HOPE & the NIH in any publications or presentations and notify the Program Manager. Here are some examples of what you can include.

“Research reported in this publication was supported by the NIAID of the National Institutes of Health under award number UM1AI164559, with co-funding support from NIDA, NIMH, NHLBI, the NIDDK, and the NINDS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

“This research was supported by NIAID award number UM1AI164559, co-funded by NHLBI, NIDA, NIMH, NINDS, and NIDDK.”

Hello HOPEians,

Please find below the action items from the RF3 meeting on December 5, 2022. If you have any questions about the meeting or action items please reach out to Dr. Melanie Ott and Dr. Priti Kumar. 

Updates:

Today we discussed the SAB report including its strengths and weaknesses. It was unclear how reticuloendothelial uptake of lipid nanoparticles will be minimized. Niren explains that they need high surface coverage, so they will target liposomes with nanobodies. They will use conjugation coding at the beginning stages, to combine Peg coding. 

Another weakness was some of the work on gene excision approaches has already received approval for clinical assessment and will be restricted to HIV-infected subjects who have cancer. HOPE might consider the “Last Gift” cohort of Davey Smith at UCSD. Melanie connected Jan Chemnitz with Davey after this meeting to start potential work with “Last Gift” patients for an 8-day clinical trial. 

We will continue our collaboration with Eric Verdin for rapamycin group experiments.

The Kumar lab is working on prime editing and improving gene editing efficiencies to target more T-cells.  Additional host gene editing will be done with CCTN1 (Cyclin T1) or CCR5.  Targeting CD4+ and CD7+ cells minimizes targeting of hematopoietic stem cells.  They will look at GFP expression in humanized mice for a longer duration. Viral titers were too highly concentrated and may have precipitated.  Additional AAV2, AAV6, and AAV2/AAV6 hybrid stocks are being prepared by Ulrike’s group and will be sent to Priti’s group for testing in primary cells. 

Another concern the SAB had was the lack of attention science is giving to global solutions for cure in terms of expense and accessibility. HOPE already works with two “Global South” sites in Brazil and Uganda.  These groups could be more integrated into the RF3 program. 

Methylation is protective and continuous demethylation may cause DNA damage.  However, highly methylated DNA will be more resistant to gene editing. Michael Corley shared an article: A modular dCas9-based recruitment platform for combinatorial epigenome editing. 

Other general lab updates are: Priti is talking to the editor of Nature about her newest publication. The Kumar Lab is working with Susana Valente and Victor Garcia on a mice study. Ulrike is producing AAV and sending another batch to the Kumar Lab. She is also working on JLAT cell lines and lentiviruses with Brec1 expression. Ulrike is working on a cell line wish list for non-T-cell lines with a single copy of LTR GFP. Francisco is also interested in a reporter cell line that can be transfected with high efficiency.

The next time we meet, Fran and Michael will go over two papers they introduced today.

Actions:

• (Finished) Melanie – Connect Jan Chemnitz with Davey Smith to start work with “Last Gift” cohort

• (Finished) Melanie – Discuss with Eric Verdin about Rapamycin group experiments

• Niren – Combine and put a Peg coding on the PLGA, use conjugation coding and do this at the beginning. Try more extensive pegylation

• Kumar lab- Connect with Ursula for biochemistry for host gene targeting

• Bring Esper onto RF3 to address their global solutions concerns

• Fran – send paper

• Michael – Share mice tissue flash freezing protocols with Priti

  • Priti can test materials sent

• Niren – Send LNPs to Priti for the Kumar lab to test – Transfection of primary human t cells with aptamer target LNPs with heart tissues

• Ulrike meeting with Fran to look at data from a previous student for Brec off suppression

  • Ulrike-Docs inducible vectors, prepping DNA, send maps and constructs to Fran

  • Send new AV to Priti

• Lish – work on MTA for this (Brec, latency models), Ulrike to send MTA contact officer to Lish

Announcements:

• If you are attending the Miami Meeting and would like to join the HOPE dinner on 12/12 Please let Robert and me know. 

• Check out the Community Jam Board to help address some of our community’s concerns

• The HOPE Collaboratory-wide meeting is on January 17.

• The next RF3 Meeting is February 6th. Please come prepared with some updates. 

• Please Acknowledge HOPE & the NIH in any publications or presentations and notify the Program Manager. Here are some examples of what you can include. 

“Research reported in this publication was supported by the NIAID of the National Institutes of Health under award number UM1AI164559, with co-funding support from NIDA, NIMH, NHLBI, the NIDDK, and the NINDS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

“This research was supported by NIAID award number UM1AI164559, co-funded by NHLBI, NIDA, NIMH, NINDS, and NIDDK.”

Hello HOPEians,

Please find below the summary and action items from the RF3 meeting on October 27, 2022. If you have any questions about the meeting or action items please reach out to Dr. Melanie Ott and Dr. Priti Kumar. 

Updates:

Priti Kumar shared that her lab has started some spironolactone experiments with mice, in collaboration with the Valente lab about using pellets. In a couple of months, they will look at rebound for the silencing experiments. She has some CURE infection data with ART (only looking at nanoluciferase). 

Micahel Corely discussed that they are running new single-cell studies. They are flash-freezing tissues from mice using liquid nitrogen. He shared that the brain is the hardest to get sequencing from. Nuclei from the tissues can be isolated and it looks like it is working. 

Ulrike Lange started to test the nanobody CD4 and found transfection is successful in T cells.  Martin started experimenting with transfecting cell lines compared to primary cells and found less transfection in the primary cell system. They have been producing new batches of the nanobodies and the first batch of purified CD4-Nanobody AB6 is to be made and sent to Priti.  Priti mentioned that promoter selection will be key to determining efficacy in Rhesus macaques versus mice.  Ulrike’s group is preparing a summary of cell line models of HIV latency to test Brec1 suppression of HIV.  Ulrike will initiate MTA with Lish’s group for material transfer.  Michael proposed an experiment where GFP+/- JLAT cells were sorted prior to BREC1 transfection to test the recombinase efficacy in active and “latent” cells.  Ulrike’s group is preparing a summary of cell line models of HIV latency to test Brec1 suppression of HIV.  Ulrike will initiate MTA with Lish’s group for material transfer.  Michael proposed an experiment where GFP+/- JLAT cells were sorted prior to BREC1 transfection to test the recombinase efficacy in active and “latent” cells.

Niren Murthy updated on his LNP work.  He mentioned that negatively charged lipids can increase spleen localization.  Although this is known in non-humanized mice this effect is unknown in humanized mice.  In collaboration with the Wang lab at UC-Davis, they put IV injected neg-LNP/CRE mRNA into adult Ai9 mice (n=3).  30 minutes post-injection, spleen cells were analyzed by flow cytometry. Transfection in mice with negatively charged lipids indicates CD3+ T cells are still transfected (7.9% & 8.3% of CD3+ T cells received and expressed the transgene). Lish asked about myeloid cell transfection.  CD11C+ cells did not receive/express the transgene.  Transfection of primary human T cells with aptamer targeting LNPs is being tested for gene delivery to primary human T cells.  Preliminary data show little toxicity. Although the two formulations only showed ~1% transfection) increased doses can be tried.

Melanie Ott and Francisco Belinchon shared information about his transfection experiment and there was not a high enough efficiency with Jurkat cells. Francisco completed Brec1 (BrecOff from Ulrike) transfection in JLATs using nucleofection.  ~0.2% transfection efficiency but no effect on HIV suppression was seen.  Repeats are being done with lentiviral vectors.  Niren mentioned Brec1 is finicky. Permanent expression may be necessary and higher levels of Brec1 are required for efficacy.

-Zoom call between Ulrike and Francisco is needed next week.  

-Western blots to verify Brec1 protein expression are needed.  

-Sorting cells may be one way to delineate the effect of BrecOff in HIV suppression in JLATs.

-Francisco is still optimizing/testing the Piggyback vector and CRISPRoff system, taken over from Martin.

 -Doxycycline inducible vectors to be sent to Francisco from Ulrike’s group (maps and construct).

Actions:

• Michael – Share mouse tissue flash freezing protocols with Priti (test materials sent)

• Niren – Send LNPs to Priti for the Kumar lab to test – Transfection of primary human t cells with aptamer target LNPs with heart tissues

• Ulrike meeting with Francisco to look at data from a previous student for Brec off suppression

  • Ulrike-Docs inducible vectors, prepping DNA, send maps and constructs to Francisco

  • Send new AV to Priti

• Lish – work on MTA for this (Brec, latency models), Ulrike to send MTA contact officer to Lish

Announcements:

• If you are attending the Miami Meeting and would like to join the HOPE dinner on 12/12 Please let Robert and me know. 

• The HOPE Collaboratory-wide meeting is on November 21st.

• The next RF3 Meeting is December 5th. Please come prepared with some updates. 

• Please Acknowledge HOPE & the NIH in any publications or presentations and notify the Program Manager. Here are some examples of what you can include. 

“Research reported in this publication was supported by the NIAID of the National Institutes of Health under award number UM1AI164559, with co-funding support from NIDA, NIMH, NHLBI, the NIDDK, and the NINDS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

“This research was supported by NIAID award number UM1AI164559, co-funded by NHLBI, NIDA, NIMH, NINDS, and NIDDK.”

Hello HOPEians,

In Monday’s meeting on June 6th, we heard data updates from the Chemnitz and Lange Labs. They explained the construction and functional characterization of an enzymatically dead Brec1 and the generation of different expression plasmids for brec1 and dBrec1. They also went over CD4-specific AAV2 vectors using nanobody capsid engineering. Priti gave a quick update on using CRISPR-BE (BE4) targeted to TAR to inhibit HIV; initial LTR reporter assays show reduced luciferase expression, next they will test using Ya-chi Ho’s clonal cell lines. Priti shared the paper “Efficient viral delivery of Cas9 into human safe harbor” and Nadia shared “Why drug delivery is the key to new medicines”.

There is a working group meeting on CRISPRoff efforts and relevant data on June 13th at 10am PT. Joining information is on the HOPE calendar.

Here are the updated actions from our last meeting. If you have any questions about the meeting or action items please reach out to Melanie and Priti. 

Actions:

• (In progress) Priti have a meeting with Ulrike 
  • Discuss CD7 nanobodies and adding RSV molecules to AAV for targeted delivery
• Jan – Generate a Brec1 construct using an SFFV promoter for Priti

Long-term Actions:

• (In progress) Priti – Provide mouse tissues to Lish for scRNA-seq
  • Lish to set up a pipeline for sequencing and analysis
  • Potentially going to Yale to do initial steps on site
• Priti- Continue to work on Brec1 delivery using a lenti or VLP based methods

Announcements:

• The July 4th meeting is canceled for the holiday
• The next meeting is scheduled for Aug 1st and we will host a HOPE – CRISPR for Cure Joint Meeting with Guest Speakers – Dr. Kamel Khalili and Dr. Tricia Burdo

Hello HOPEians,

In yesterday’s meeting, Niren Murthy gave updates about the LNP delivery systems developed in his laboratory with the goal of transfecting mRNAs in human T cells and HSCs. Stephen Yeung gave an update on the surface markers subgroup meeting where it was decided to focus on PD1 and TIGIT as markers of cells with latent HIV.

For our next meeting on June 6th, we will hear data updates from Chemnitz and Lange Labs. Here are updated actions from our meeting in May, we will discuss these at the next meeting. If you have any questions about the meeting or action items please reach out to Melanie and Priti. 

Actions:

• (In progress) Priti have a meeting with Ulrike 
  • Discuss CD7 nanobodies and adding RSV molecules to AAV for targeted delivery
• Jan – Generate a BREC1 construct using an SFFV promoter for Priti
• (In progress) Ulrike – set up a meeting with Warner to discuss good CRISPRi guides
• All – If you have not already, please complete the HOPE Member Introduction form

Long-term Actions:

• (In progress) Priti – Provide mouse tissues to Lish for scRNA-seq
  • Lish to set up a pipeline for sequencing and analysis
  • Potentially going to Yale to do initial steps on site
• Priti- Continue to work on Brec1 delivery using a lenti or VLP based methods

Announcements:

• The next meeting is scheduled for June 6th. Chemnitz and Lange labs to present.
• The email hope-rf3-members@gladstone.ucsf.edu can be used to reach the whole RF3 group
• Share announcements and achievements for the HOPE Twitter or Website by filling out the Social Media Shoutout form.

​​Hello HOPEians,

In yesterday’s RF3 meeting, we went over past actions items with the following updates:

1. Phil Norris shared HIV-specific CD4+ granzyme clones with Ndhlovu and Nixon labs; they are following up with the function of these clones.
2. Chemnitz and Lange labs working on defective BREC; constructs are made and they are testing the functionality of these constructs. They will provide an update on progress at the RF3 meeting on June 6th.
3. Murthy lab testing lipid nanoparticle delivery in PBMCs, initial tests show low transfection efficiency, they are working on new formulations and testing in mouse models. Currently focusing on mRNA delivery instead of protein delivery of BREC due to difficulties in purification. They will provide an update on progress and discuss CAR-T cell delivery at the next meeting on May 2nd.
4. Greene lab updated on CRISPRi work. The probability of the suppression is only good while the Cas is physically obstructing the promoter.
5. The use of CD4 nanobodies for delivery is on pause because the molecule is not endocytosed, Priti will follow up on possibly using a CD7 nanobody. 

For our next meeting on May 2nd, we will resume our normal round table format and hear data updates from Niren. Here are updated actions from our meeting in March, we will discuss these at the next meeting. If you have any questions about the meeting or action items please reach out to Melanie and Priti. 

Actions:

• Priti set up a meeting with Ulrike
  • Discuss CD7 nanobodies and adding RSV molecules to AAV for targeted delivery
• Sydney – Set up a single-cell RNA sequencing meeting
  • Invitees: Lish, Melanie, Nadia, Priti
• Jan – Generate a BREC1 construct using an SFFV promoter for Priti
• Melanie – send Priti a Tat expression vector using EF1a promoter (WT & defective mutant)
• Melanie Lab – Find  a good Tat antibody for ChIP
• Ulrike – set up a meeting with Warner to discuss good CRISPRi guides
• All – If you have not already, please complete the HOPE Member Introduction form

Long-term Actions:

• (In progress) Priti – Provide mouse tissues to Lish for scRNA-seq
  • Lish to set up a pipeline for sequencing and analysis
  • Potentially going to Yale to do initial steps on site
• Priti- Continue to work on Brec1 delivery using a lenti or VLP based methods

Announcements:

• The next meeting is scheduled for May 2nd.
• The email hope-rf3-members@gladstone.ucsf.edu can be used to reach the whole RF3 group
• Share announcements and achievements for the HOPE Twitter or Website by filling out the Social Media Shoutout form.

Presenters for next meeting: 

• 5/2 – Murthy Lab and update on cell surface markers from Stephen (Ndhlovu Lab)
• 6/6 – Update from Chemnitz and Lange Labs

Hello HOPEians,

In today’s RF3 meeting, we had an external speaker, Dr. Ya-Chi Ho from Yale. She gave a presentation titled ‘The clonal expansion dynamics of HIV-1-infected cells revealed by single-cell multiomics’.

For our next meeting on April 4th, we will resume our normal round table format. Here are actions from our meeting in February, we will discuss these at the next meeting. If you have any questions about the meeting or action items please reach out to Melanie and Priti. 

Actions:

• Doug – Ask Phil Norris for the CD4+ granzyme positive clones
• (In progress) Jan send Niren contacts and protocol for Brec purification
  • Jan – Send update on defective Brec and send material for ChIP to Melanie
• Hesong – Work with Bharath and Priti on lipid nanoparticles in primary cells and mice

• (In progress) Martin Hamann/Ulrike – Send Niren the expression vector for the nanobodies
• Priti – Find out if it is possible to get access to Ya-chi Ho’s scRNA-seq data
• Priti or Niren present at the gene therapy amfAR meeting (March 25-27)
• All – If you have not already, please complete the HOPE Member Introduction form

Long-term Actions:

• (In progress) Priti – Provide mouse tissues to Lish for scRNA-seq
  • Lish to set up a pipeline for sequencing and analysis
• Priti- Continue to work on Brec1 delivery using a lenti or VLP based methods

Announcements:

• The next meeting is scheduled for April 4th.
• The email hope-rf3-members@gladstone.ucsf.edu can be used to reach the whole RF3 group
• Share announcements and achievements for the HOPE Twitter or Website by filling out the Social Media Shoutout form.

Hello HOPEians,

In yesterday’s RF3 meeting, Jan gave an overview of the development and clinical testing of Brec1 and there was an update from Niren on the delivery of mRNA using lipid nanoparticle formations.

Please find below the action items from the RF3 meeting on February 7th.  If you have any questions about the meeting or action items please reach out to Melanie and Priti. 

Actions:

• Priti or Niren present at the gene therapy amfAR meeting (March 25-27)
• Jan send Niren contacts and protocol for Brec purification
  • Jan – Send update on defective Brec and send material for ChIP to Melanie
• Hesong – Work with Bharath and Priti on lipid nanoparticles in primary cells and mice

• (In Progress) Martin Hamann/Ulrike – Send Niren the expression vector for the nanobodies
• The surface marker subgroup meeting is scheduled for Feb 10th at 10am PT (1pm ET). Invitees include Lish (Stephen Yueng), Melanie (Bharath), Priti, Nadia, Niren, and Danielle.
• Priti – Find out if it is possible to get access to Ya-chi Ho’s scRNA-seq data
• All – If you have not already, please complete the HOPE Member Introduction form

Long-term Actions:

• (In progress) Priti – Provide mouse tissues to Lish for scRNA-seq
  • Lish to set up a pipeline for sequencing and analysis
• Priti- Continue to work on Brec1 delivery using a lenti or VLP based methods

Announcements:

• The next meeting is scheduled for March 7th.
• The email hope-rf3-members@gladstone.ucsf.edu can be used to reach the whole RF3 group
• Please keep Sydney and Danielle in the loop when scheduling subgroup meetings
• Share announcements and achievements for the HOPE Twitter or Website by filling out the Social Media Shoutout form.